Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Seladelpar lysine by Gilead Sciences for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Seladelpar lysine is under clinical development by Gilead Sciences and currently in Pre-Registration for Primary Biliary Cholangitis (Primary Biliary Cirrhosis)....
Risk adjusted net present value: What is the current valuation of Gilead Sciences's Seladelpar lysine?
Seladelpar lysine is a small molecule commercialized by Gilead Sciences, with a leading Pre-Registration program in Primary Biliary Cholangitis (Primary...
Magrolimab by Gilead Sciences for Colorectal Cancer: Likelihood of Approval
Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Magrolimab by Gilead Sciences for Ovarian Cancer: Likelihood of Approval
Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
GS-9716 by Gilead Sciences for Solid Tumor: Likelihood of Approval
GS-9716 is under clinical development by Gilead Sciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
GS-4528 by Gilead Sciences for Melanoma: Likelihood of Approval
GS-4528 is under clinical development by Gilead Sciences and currently in Phase I for Melanoma. According to GlobalData, Phase I...
Zinlirvimab by Gilead Sciences for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
Zinlirvimab is under clinical development by Gilead Sciences and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS)....
GS-0272 by Gilead Sciences for Systemic Lupus Erythematosus: Likelihood of Approval
GS-0272 is under clinical development by Gilead Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
Magrolimab by Gilead Sciences for Head And Neck Cancer: Likelihood of Approval
Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Head And Neck Cancer. According to...
GS-1720 by Gilead Sciences for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
GS-1720 is under clinical development by Gilead Sciences and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS)....
KITE-222 by Gilead Sciences for Mantle Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...
KITE-222 by Gilead Sciences for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...
KITE-222 by Gilead Sciences for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Chronic Lymphocytic Leukemia (CLL). According to...
KITE-222 by Gilead Sciences for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
KITE-222 by Gilead Sciences for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to...
KITE-222 by Gilead Sciences for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According...
KITE-222 by Gilead Sciences for Burkitt Lymphoma: Likelihood of Approval
KITE-222 is under clinical development by Gilead Sciences and currently in Phase II for Burkitt Lymphoma. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Gilead Sciences's KITE-222?
KITE-222 is a gene-modified cell therapy commercialized by Gilead Sciences, with a leading Phase II program in Primary Mediastinal B-Cell...
GS-6212 by Gilead Sciences for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval
GS-6212 is under clinical development by Gilead Sciences and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS)....
Tilpisertib fosmecarbil by Gilead Sciences for Ulcerative Colitis: Likelihood of Approval
Tilpisertib fosmecarbil is under clinical development by Gilead Sciences and currently in Phase II for Ulcerative Colitis. According to GlobalData,...